AstraZeneca adds fourth trial: Phase 3 AZD6234 in obesity, adjunct to incretins

AstraZeneca's latest trial activity includes a newly registered Phase 3 study alongside three previously reported items.

• AZD6234 (lenbelintide), a weekly subcutaneous injection, was registered for a Phase 3 trial called "SELENE 3" in adults with obesity or overweight and at least one weight-related comorbidity, with or without type 2 diabetes. The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity, comparing it to placebo in percent body weight change from baseline at 68 weeks of treatment.¹ Study treatment will be added on to participants' stable dose of background incretin-based therapies.¹ Estimated enrollment is 500 participants.¹
• Elecoglipron, an oral GLP-1 receptor agonist also known as AZD5004, is enrolling in a Phase 3 trial called "EMBOLD-Asia" for obesity or overweight with or without type 2 diabetes. The primary outcome is percent change from baseline to Week 52 in body weight.² Estimated enrollment is 351 participants.²
• AZD0292, a bispecific IgG1k monoclonal antibody, is recruiting for a Phase 2 trial called "BREEZE" in Chinese patients with bronchiectasis and chronic Pseudomonas aeruginosa colonization. The study aims to assess the efficacy, safety, and PK of AZD0292 administered IV, as compared to placebo, in participants 18 years of age and older.³ Estimated enrollment is 84 participants.³
• Kaiser Permanente is recruiting for an observational study called "REFOCUS-HTN US-WEST," with AstraZeneca as a collaborator, to study aldosterone's role in hypertension. The SCALED sub-study will enroll a subset of about 500 participants from the REFOCUS-HTN cohort for prospective data collection.⁴